>>>   Click for Diagenode’s approach to COVID-19

Integrated epigenetic biomarkers in circulating cell-free DNA as a robust classifier for pancreatic cancer.

Cao F, Wei A, Hu X, He Y, Zhang J, Xia L, Tu K, Yuan J, Guo Z, Liu H, Xie D, Li A

BACKGROUND: The high lethal rate of pancreatic cancer is partly due to a lack of efficient biomarkers for screening and early diagnosis. We attempted to develop effective and noninvasive methods using 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) markers from circulating cell-free DNA (cfDNA) for the detection of pancreatic ductal adenocarcinoma (PDAC). RESULTS: A 24-feature 5mC model that can accurately discriminate PDAC from healthy controls (area under the curve (AUC) = 0.977, sensitivity = 0.824, specificity = 1) and a 5hmC prediction model with 27 features demonstrated excellent detection power in two distinct validation sets (AUC = 0.992 and 0.960, sensitivity = 0.786 and 0.857, specificity = 1 and 0.993). The 51-feature model combining 5mC and 5hmC markers outperformed both of the individual models, with an AUC of 0.997 (sensitivity = 0.938, specificity = 0.955) and particularly an improvement in the prediction sensitivity of PDAC. In addition, the weighted diagnosis score (wd-score) calculated with the 5hmC model can distinguish stage I patients from stage II-IV patients. CONCLUSIONS: Both 5mC and 5hmC biomarkers in cfDNA are effective in PDAC detection, and the 5mC-5hmC integrated model significantly improve the detection sensitivity.

MagMeDIP kit
IPure kit

Share this article

July, 2020


Products used in this publication

  • default alt
    IPure kit v2
  • MagMeDIP qPCR Kit box
    MagMeDIP qPCR kit
  • MagMeDIP-seq Package
    MagMeDIP-seq Package
  • default alt
    MagMeDIP-seq Pacakge V2


  • DNA methylation workshop: Become an expert at RRBS
    Oct 1-Oct 31, 2021
  • Dutch Chromatin Meeting
    Radboud UMC, Geert Grooteplein 15, 6525 EZ Nijmegen, The Netherlands, Experience center, route 292 to 307
    Nov 12, 2021



The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics